Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Top Stories >>  Teva to produce new biosimilar drugs outside Israel

Teva to produce new biosimilar drugs outside Israel

January 10, 2019 By firstwordpharma

People close to the matter revealed that Teva plans to manufacture a new biosimilar outside Israel, Globes reported Wednesday.


It was previously believed that the drugmaker would use its Kfar Saba site, which manufactures Copaxone, to produce biosimilars and complex generics.


Meanwhile, labour disputes at the site may have influenced Teva's decision to manufacture the drug outside the country.


A labour dispute was declared at the facility earlier this month after management offered staff a 1.4-percent pay increase after no pay hike in 2018.


"We have no desire to harm the company, but we will not allow the company to harm us," commented Teva Kfar Saba workers' committee chairperson Eliran Kozlik, adding "this site is more important to us than to managers who serve one or two terms. We will stay here; it is our home."

Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat